Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies.

Phalora PK, Sherer NM, Wolinsky SM, Swanson CM, Malim MH.

J Virol. 2012 Nov;86(21):11712-24. doi: 10.1128/JVI.00595-12. Epub 2012 Aug 22.

2.

Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.

Ara A, Love RP, Follack TB, Ahmed KA, Adolph MB, Chelico L.

J Virol. 2017 Jan 18;91(3). pii: e02230-16. doi: 10.1128/JVI.02230-16. Print 2017 Feb 1.

3.

Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies.

Wichroski MJ, Robb GB, Rana TM.

PLoS Pathog. 2006 May;2(5):e41. Epub 2006 May 12.

4.

Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging.

Wang T, Tian C, Zhang W, Sarkis PT, Yu XF.

J Mol Biol. 2008 Jan 25;375(4):1098-112. Epub 2007 Nov 13.

PMID:
18067920
5.

Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.

Armitage AE, Deforche K, Welch JJ, Van Laethem K, Camacho R, Rambaut A, Iversen AK.

J Virol. 2014 Nov;88(21):12882-94. doi: 10.1128/JVI.01460-14. Epub 2014 Aug 27.

7.

APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.

Li J, Chen Y, Li M, Carpenter MA, McDougle RM, Luengas EM, Macdonald PJ, Harris RS, Mueller JD.

J Mol Biol. 2014 Mar 20;426(6):1296-307. doi: 10.1016/j.jmb.2013.12.014. Epub 2013 Dec 17.

8.

Mov10 and APOBEC3G localization to processing bodies is not required for virion incorporation and antiviral activity.

Izumi T, Burdick R, Shigemi M, Plisov S, Hu WS, Pathak VK.

J Virol. 2013 Oct;87(20):11047-62. doi: 10.1128/JVI.02070-13. Epub 2013 Aug 7.

9.

Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.

Gillick K, Pollpeter D, Phalora P, Kim EY, Wolinsky SM, Malim MH.

J Virol. 2013 Feb;87(3):1508-17. doi: 10.1128/JVI.02587-12. Epub 2012 Nov 14.

10.

HIV restriction by APOBEC3 in humanized mice.

Krisko JF, Martinez-Torres F, Foster JL, Garcia JV.

PLoS Pathog. 2013 Mar;9(3):e1003242. doi: 10.1371/journal.ppat.1003242. Epub 2013 Mar 28.

11.

Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Desimmie BA, Delviks-Frankenberrry KA, Burdick RC, Qi D, Izumi T, Pathak VK.

J Mol Biol. 2014 Mar 20;426(6):1220-45. doi: 10.1016/j.jmb.2013.10.033. Epub 2013 Nov 2. Review.

12.

Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.

Baig TT, Feng Y, Chelico L.

J Virol. 2014 Dec;88(24):14380-95. doi: 10.1128/JVI.02484-14. Epub 2014 Oct 1. Erratum in: J Virol. 2017 Mar 13;91(7):.

13.

Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.

Refsland EW, Hultquist JF, Harris RS.

PLoS Pathog. 2012;8(7):e1002800. doi: 10.1371/journal.ppat.1002800. Epub 2012 Jul 12.

14.

Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1.

Apolonia L, Schulz R, Curk T, Rocha P, Swanson CM, Schaller T, Ule J, Malim MH.

PLoS Pathog. 2015 Jan 15;11(1):e1004609. doi: 10.1371/journal.ppat.1004609. eCollection 2015 Jan.

15.

Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation.

Kobayashi T, Koizumi Y, Takeuchi JS, Misawa N, Kimura Y, Morita S, Aihara K, Koyanagi Y, Iwami S, Sato K.

J Virol. 2014 May;88(10):5881-7. doi: 10.1128/JVI.00062-14. Epub 2014 Mar 12.

16.

Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors.

Russell RA, Wiegand HL, Moore MD, Schäfer A, McClure MO, Cullen BR.

J Virol. 2005 Jul;79(14):8724-31.

17.

Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms.

Ara A, Love RP, Chelico L.

PLoS Pathog. 2014 Mar 20;10(3):e1004024. doi: 10.1371/journal.ppat.1004024. eCollection 2014 Mar.

18.

Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association.

Niewiadomska AM, Tian C, Tan L, Wang T, Sarkis PT, Yu XF.

J Virol. 2007 Sep;81(17):9577-83. Epub 2007 Jun 20.

19.

Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.

Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, Ono A, Freed EO, Hu WS, Pathak VK.

J Biol Chem. 2004 Aug 20;279(34):35822-8. Epub 2004 Jun 20.

20.

A novel HIV-1 restriction factor that is biologically distinct from APOBEC3 cytidine deaminases in a human T cell line CEM.NKR.

Zhou T, Han Y, Dang Y, Wang X, Zheng YH.

Retrovirology. 2009 Apr 3;6:31. doi: 10.1186/1742-4690-6-31.

Supplemental Content

Support Center